Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
Abstract Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-03-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.2688 |
| _version_ | 1818506338006728704 |
|---|---|
| author | Kana Nagashima Shohei Kikuchi Satoshi Iyama Chisa Fujita Akari Goto Hiroto Horiguchi Masayoshi Kobune |
| author_facet | Kana Nagashima Shohei Kikuchi Satoshi Iyama Chisa Fujita Akari Goto Hiroto Horiguchi Masayoshi Kobune |
| author_sort | Kana Nagashima |
| collection | DOAJ |
| description | Abstract Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT. |
| first_indexed | 2024-12-10T22:03:12Z |
| format | Article |
| id | doaj.art-55993954f2b548608787685d9a6e4b09 |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-12-10T22:03:12Z |
| publishDate | 2020-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-55993954f2b548608787685d9a6e4b092022-12-22T01:31:51ZengWileyClinical Case Reports2050-09042020-03-018346646810.1002/ccr3.2688Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remissionKana Nagashima0Shohei Kikuchi1Satoshi Iyama2Chisa Fujita3Akari Goto4Hiroto Horiguchi5Masayoshi Kobune6Department of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Hematology Sapporo Medical University School of Medicine Sapporo JapanAbstract Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.https://doi.org/10.1002/ccr3.2688brentuximab vedotinclassical Hodgkin lymphomalate‐relapse |
| spellingShingle | Kana Nagashima Shohei Kikuchi Satoshi Iyama Chisa Fujita Akari Goto Hiroto Horiguchi Masayoshi Kobune Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission Clinical Case Reports brentuximab vedotin classical Hodgkin lymphoma late‐relapse |
| title | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
| title_full | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
| title_fullStr | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
| title_full_unstemmed | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
| title_short | Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission |
| title_sort | successful brentuximab vedotin monotherapy against late relapse of classical hodgkin lymphoma 6 years after first remission |
| topic | brentuximab vedotin classical Hodgkin lymphoma late‐relapse |
| url | https://doi.org/10.1002/ccr3.2688 |
| work_keys_str_mv | AT kananagashima successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT shoheikikuchi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT satoshiiyama successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT chisafujita successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT akarigoto successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT hirotohoriguchi successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission AT masayoshikobune successfulbrentuximabvedotinmonotherapyagainstlaterelapseofclassicalhodgkinlymphoma6yearsafterfirstremission |